<DOC>
	<DOCNO>NCT02446132</DOCNO>
	<brief_summary>This extension study Phase 3 Studies 15-AVP-786-301 15-AVP-786-302 , also allow participant Phase 2 Study 12-AVR-131 include .</brief_summary>
	<brief_title>Long Term , Extension Study Safety Efficacy AVP-786 ( Deuterated d6 Dextromethorphan Hydrobromide d6-DM/Quinidine Sulfate Q ) Treatment Agitation Patients With Dementia Alzheimer 's Type</brief_title>
	<detailed_description>Participant successfully complete Studies 15-AVP-786-301 , 15-AVP-786-302 , 12-AVR-131 . Participants enrol study approximately 52 week . Approximately 550 participant enrol approximately 110 center North America . All participant enrol receive AVP-786 ; treatment dose assign mask participant , investigator , study staff , sponsor .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<mesh_term>Quinidine gluconate</mesh_term>
	<criteria>Participant successfully complete Studies 15AVP786301 , 15AVP786302 , 12AVR131 Participants Study 12AVR131 diagnosis probable AD accord 2011 National Institute AgingAlzheimer 's Association ( NIAAA ) work group criterion Either outpatient resident assistedliving facility skilled nursing home Participants Study 12AVR131 clinically significant , moderate/severe agitation least 2 week prior baseline Participants Study 12AVR131 diagnosis agitation must meet International Psychogeriatric Association ( IPA ) provisional definition agitation Participants Study 12AVR131 Clinical Global Impression Change ( CGIS ) score assess Agitation ≥ 4 ( moderately ill ) baseline Participants Study 12AVR131 MiniMental State Examination ( MMSE ) score 6 26 ( inclusive ) screen baseline Participants coexistent clinically significant unstable systemic disease could confound interpretation safety result study ( e.g. , malignancy , poorly control diabetes , poorly control hypertension , unstable pulmonary , renal hepatic disease , unstable ischemic cardiac disease , dilate cardiomyopathy , unstable valvular heart disease ) Participants determine high imminent risk fall study base clinical evaluation investigator Participants currently use NUEDEXTA® 4 week precede baseline</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>